NeoGenomics (MEX:NEO) Other Current Payables: MXN0 Mil (As of Mar. 2026)


MEX:NEO NeoGenomics Inc MEX:NEO
71 GF Score
Price MXN176.40
GF Value MXN206.01
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Other Current Payables?

NeoGenomics MEX:NEO 71 Other Current Payables is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:NEO with a GF Score™ of 71/100 and a GF Value™ of MXN206.01 (Modestly Undervalued). The stock has 6 warning signs investors should review.

NeoGenomics's Other Current Payables for the quarter that ended in Mar. 2026 was MXN0 Mil.

NeoGenomics Other Current Payables Related Terms

NeoGenomics Other Current Payables Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Other Current Payables Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NeoGenomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:NEO
71GF Score
NeoGenomics Inc MEX:NEO
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of MXN0 Mil mean?
NeoGenomics (MEX:NEO) has a Other Current Payables of MXN0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Other Current Payables too high?
NeoGenomics' current Other Current Payables is MXN0 Mil. Overall, NeoGenomics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Other Current Payables compare to WGS and CDNA?
NeoGenomics' Other Current Payables of MXN0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Diagnostics & Research company?
A good Other Current Payables depends on the Medical Diagnostics & Research industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on NeoGenomics and its competitors. NeoGenomics's current Other Current Payables is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (MEX:NEO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN206.01, compared to a current price of MXN176.40 — trading 14.4% below its estimated fair value. The current Other Current Payables is MXN0 Mil. NeoGenomics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Other Current Payables is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of MXN176.40 is trading 14.4% below its estimated GF Value™ of MXN206.01. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for MEX:NEO:

  • Other Current Payables: MXN0 Mil
  • GF Value™: MXN206.01 vs. price of MXN176.40 (14.4% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
71GF Score

Get the complete analysis for MEX:NEO

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN206.01
GF Value